Clearmind’s MEAI Achieves 20% Mouse Weight Loss, Preserves Lean Mass
Clearmind Medicine's MEAI achieved ~20% weight loss with preserved lean muscle in preclinical obese mice and improved insulin sensitivity and fatty liver reversal. The company filed new obesity and metabolic disorder patents, partnered on an intranasal delivery formulation, and advanced its Phase I/IIa alcohol use disorder trial.
1. Preclinical Efficacy Data
In diet-induced obese mice, MEAI treatment delivered approximately 20% body weight reduction while significantly decreasing fat mass and preserving lean muscle. The compound also boosted fat oxidation, enhanced insulin sensitivity, reversed fatty liver disease and normalized key metabolic parameters in these models.
2. Unique Mechanism of Action
Unlike gut-targeted GLP-1 and GLP-1/GIP agonists, MEAI acts on the brain’s monoaminergic pathways to disrupt rigid eating behaviors, promote neuroplasticity and modulate energy balance. This brain-focused approach targets compulsive and emotional overeating, offering potential long-term behavioral benefits.
3. Development Milestones and Partnerships
Clearmind has filed new patents for obesity and metabolic indications and entered a collaboration to develop an intranasal MEAI formulation for enhanced delivery. Meanwhile, its FDA-approved Phase I/IIa alcohol use disorder trial has completed cohorts with data readouts expected soon.